Product Name :
PSB-SB-487

CAS No.:
1399049-81-0

Purity :
99.36%

Shipping:
Room temperature in the continental U.S. Other areas may vary.

Storage :
Powder: -20°C, 3 years; 4°C, 2 yearsIn solvent: -80°C, 6 months; -20°C, 1 month

SMILES:
O=C1C(CC2=CC=CC=C2O)=CC3=C(O)C=C(C(C)(C)CCCCCCC)C=C3O1

Product Description :
PSB-SB-487 is a potent GPR55 antagonist and CB2 agonist with an IC50 value of 0.113 µM for GPR55, and a Ki value of 0.292 µM for human CB2. PSB-SB-487 can be used for researching diabetes, Parkinson’s disease, neuropathic pain, and cancer.

Formula:
C26H32O4

Molecular Weight :
408.53

Synonyms:

Additional Information:
|CAS No.{{Besifovir} site|{Besifovir} HBV|{Besifovir} Purity & Documentation|{Besifovir} In Vivo|{Besifovir} custom synthesis|{Besifovir} Epigenetic Reader Domain} 1399049-81-0 ; |Formula C26H32O4 ; |Molecular Weight 408.{{Donanemab} site|{Donanemab} Neuronal Signaling|{Donanemab} Purity & Documentation|{Donanemab} Description|{Donanemab} manufacturer|{Donanemab} Cancer} 53 ; |SMILES O=C1C(CC2=CC=CC=C2O)=CC3=C(O)C=C(C(C)(C)CCCCCCC)C=C3O1 ; |Target GPR55, Cannabinoid Receptor ; |Product Description PSB-SB-487 is a potent GPR55 antagonist and CB2 agonist with an IC50 value of 0.PMID:23600560 113 µM for GPR55, and a Ki value of 0.292 µM for human CB2. PSB-SB-487 can be used for researching diabetes, Parkinson’s disease, neuropathic pain, and cancer. ; |Format Solid ; |Color White to off-white ; |Purity 99.36% ; |Shipping Room temperature in the continental U.S. Other areas may vary. ; |Storage Powder: -20°C, 3 years; 4°C, 2 yearsIn solvent: -80°C, 6 months; -20°C, 1 month ; |Solubility Overview Soluble in DMSO

MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com